Yes, a competent management team with experience getting high profile molecules across the finish line.

And how about a BP partner for funding, market confidence and optics. We could possibly (and maybe should) be approaching an interim analysis soon in 2023 if we had partnered with the BP that wanted a 5 year study. The stock value would almost certainly be many multiples ahead of where it is now. And I sure don't see this management team getting it across the finish line in any remotely similar time frame as that "alleged" opporunity might have taken, as it stands now, and with the price at sub $.15 U.S.

Finally, if Zenith can gain BP partners, why can't RVX, with a narrow BoM miss and a BTD coming out of BoM?! 

It's all just mind numbing ... hey Eversana, a penny for your thoughts?